Pharnext wins Best Life-Scineces IPO France 2016 Award
January 17, 2017Pharnext, a French biopharmaceutical company focused on drugs against neurodegenerative diseases, has been named Best Life-Sciences IPO France 2016 Award.
This award is given by the London-headquartered Capital Finance International (CFI), a print journal and online resource reporting on business, economics, and finance.
The CFI judges have considered that Pharnext specialises in the development of drugs that could help treat severe unmet medical needs including neurodegenerative diseases.
Daniel Cohen, Co-Founder and Chief Executive Officer of Pharnext., commented: “We are greatly honoured to receive this Award which rewards the engagement of our teams involved in the successful completion of our IPO. It is the trust of our investors and the support of our partners which have made it possible for Pharnext to reach this crucial milestone. In line with our roadmap, we keep on intensifying our R&D efforts and further exploring the potential of our two lead Pleodrug : PXT3003 currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and PXT864 currently in Phase 2 trial for the treatment of Alzheimer’s disease. We warmly thank Capital Finance International for this prestigious Award.”
About the CFI.co Awards Programme
Each year, CFI.co seeks out individuals and organisations that contribute significantly to the convergence of economies and truly add value for all stakeholders. Reporting from frontlines of economies on the move, CFI.co realises that best practice is to be found throughout the world. The Awards Programme aims to identify and reward excellence wherever it is found. The programme aims to inspire others to further improve their own performance.
